Go To Global Site
Welcome to UCB in the United States

Sep

07

Our R&D Response to COVID-19: A Patients’ First Approach

UCB’s robust global R&D response during COVID-19 focused on our patients, employees, and our communities. Read more on our overall approach from UCB's Chief Medical Officer, Iris Loew-Friedrich.  

Sep

01

UCB’s Commitment to Students Living with Epilepsy

Each year, UCB has the honor of awarding our UCB Family Epilepsy Scholarship to deserving individuals living with epilepsy, their family members, and caregivers to help them fulfill their dreams. We realize that to truly make an impact on patients’ lives, we must go beyond developing and delivering medicines, and we are committed to helping patients and their families receive the financial support they need to live their best lives possible.

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Aug

09

Improving Diversity in Dermatology

This August, the theme for Psoriasis Action Month is ‘All of Us.’ UCB is joining the National Psoriasis Foundation to shine light on the condition’s impact on diverse populations, and celebrate the diversity and inclusivity of the psoriasis community. Read more from Rhonda Peebles, Head of U.S. Dermatology, as she shares her thoughts on racial inequities in dermatology and the steps UCB is taking to move the equity needle forward. 

Aug

07

New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Aug

05

“All of Us” vs. Psoriasis

As part of Psoriasis Action Month, Camille Lee, Head of U.S. Immunology at UCB, shares how UCB is helping find and bridge gaps in psoriatic disease care. 

Jul

28

UCB Welcomes Second Class of Virtual Interns

Tomorrow is National Intern Day 2021! We are pleased to continue our mission of investing in the next generation of the workforce by welcoming 32 student interns to our second virtual internship program.

Jul

20

Voices on Value: UCB’s Commitment to Transforming Access Through Value-Based Contracts

As our health care system shifts from volume- to value-based reimbursement, industry participation in value-based contracts (VBCs) is helping drive this transformation. Read more from Head of Rare Disease Access Strategy, Kelly Guntrum, on how UCB is transforming access through value-based contracts.

Jul

14

UCB’s 90+ Year History – Then, Now, and In the Future

UCB’s history is backed by 90+ years of innovation, transformation, and passion. These qualities include the decades of expertise in science utilized by UCB. Read more about the history of UCB then, now, and in the future. 

Jun

28

Committed to Advancing Science and Delivering Value for Patients

With more than 90 years of innovation, at UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Learn more about who we are at UCB.